



## Treatment talking points

There are several treatments being used for COVID-19. They are for different kinds of people facing different risks, and they are in extremely short supply around the county. Please do NOT go to the emergency room to seek these treatments.

### Monoclonal Antibodies (mAbs)

- Do NOT go to the emergency room seeking this treatment. Anyone interested in receiving this treatment must consult with their healthcare provider.
- Monoclonal antibodies (mAbs) work by mimicking the antibodies your body produces in response to a virus. These laboratory-produced molecules block SARS-CoV-2 (the virus that causes COVID-19) from entering your cells.
- mAbs are authorized for people ages 12+ who have tested positive for COVID-19 or have been exposed to someone who has tested positive. However, because of shortages around the country, only those who are at risk for severe disease are eligible to receive monoclonal antibody treatment

**People who are eligible to receive mAbs (from <https://combatcovid.hhs.gov/i-have-covid-19/how-do-i-know-if-im-high-risk>)**

### People over age 65

#### People over age 12 who:

- Have Obesity
- Have Diabetes
- Have Chronic Kidney disease
- Have a Heart condition like heart failure, cardiomyopathies, or high blood pressure
- Have Sickle cell disease
- Have A developmental condition like cerebral palsy
- Use Daily medication for asthma or other long-term lung disease
- Have a Dependency on regular use of medical technology like a ventilator or feeding tube
- Are pregnant
- Are taking medications that weakens the immune system

## Antivirals

- There are currently two antiviral medications authorized by the FDA for emergency use. Pfizer's Paxlovid and Merck's Molnupiravir
- These medications are in short supply. Do NOT go to the emergency room to seek treatment with these medications. You must first talk to a healthcare provider.
- Paxlovid is authorized for people ages 12 and older weighing at least 40 kg (88 pounds) with mild-to-moderate symptoms who are at high risk of developing severe disease.
- Molnupiravir is authorized for adults ages 18 and older with mild-to-moderate symptoms who are at risk of developing severe disease and do not have access to other FDA-authorized treatment options. Molnupiravir is not recommended for pregnant people or children/adolescents.
- Neither antiviral is authorized for treatment of severe COVID-19. Neither medication can prevent infection.

**Document accessibility:** For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the COVID-19 Communications Unit at 1-971-673-2411, 711 TTY or [COVID19.LanguageAccess@dhsoha.state.or.us](mailto:COVID19.LanguageAccess@dhsoha.state.or.us)